Completion of Acquisition
Novacyt S.A. has announced the completion of its acquisition of Southern Cross Diagnostics Pty Ltd through its wholly owned subsidiary, Novacyt Holdings UK Limited. This acquisition follows a previous notification on February 23, 2026, and further details regarding a Preferential Subscription Rights issue are expected to be released immediately after this announcement.
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, and Manchester, UK - 2 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that further to the notification of 23 February 2026 the acquisition of Southern Cross Diagnostics Pty Ltd by is wholly owned subsidiary, Novacyt Holdings UK Limited, has now completed.
Further details regarding a Preferential Subscription Rights issue will be announced immediately following this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.